Zuclopenthixol is an antipsychotic indicated for the management of schizophrenia. The acuphase formulation is indicated for initial treatment of acute psychosis or exacerbation of psychosis, while the depot formulation is best for maintenance. Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent.
- Mechanism
- Curator reviewed
Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
- Primary indication
- Used in the management of acute psychoses such as mania or schizophrenia.Curator reviewed · 6 structured indications
- Formula / weight
- C22H25ClN2OS · 400.965 g/mol (avg)
- First approval
- Canada, 1997
- Code names
- N05AF05
- Brand names
Resolves to
WFPIAZLQTJBIFN-DVZOWYKESA-NSMILESOCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Zuclopenthixol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account